ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial-Reference-Cited by-同舟云学术

ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial

Published:2017-11 Issue:suppl_6 Volume:19 Page:vi13-vi14
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Herrlinger Ulrich,Tzaridis Theophilos,Mack Frederic,Steinbach Joachim,Schlegel Uwe,Sabel Michael,Hau Peter,Kortman Rolf-Dieter,Krex Dietmar,Grauer Oliver,Goldbrunner Roland,Schnell Oliver,Baehr Oliver,Uhl Martin,Tabatabai Ghazaleh,Ringel Florian,Schmidt-Graf Friederike,Brehmer Stefanie,Weyerbrock Astrid,Bullinger Lars,Vajkoczy Peter,Vatter Hartmut,Schäfer Niklas,Kebir Sied,Weller Johannes,Stummer Walter,Simon Matthias,Keil Vera,Nelles Michael,Fimmers Rolf,Pietsch Torsten,Hattingen Elke,Coch Christoph,Glas Martin

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/19/suppl_6/vi13/21590733/nox168.049.pdf

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronotherapy in Glioblastoma: state of the art and future perspectives;eBioMedicine;2023-03

2. Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance;International Journal of Molecular Sciences;2020-08-06

3. ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE;Rationelle Diagnostik und Therapie in der Inneren Medizin;2020

4. Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients;British Journal of Neurosurgery;2019-08-13

5. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients;Acta Neuropathologica Communications;2019-06-05